BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Radiopharmaceuticals
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, September 22, 2023
Home » Blogs » BioWorld MedTech Perspectives » The real story: competing markets, not just emerging markets

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech

The real story: competing markets, not just emerging markets

April 13, 2011
By Omar Ford
No Comments

Often times journalists go into interviews with pretty much a clear picture of what the story is going to be. There are few surprises – that is until that one kernel of information spills from the lips of a source and it completely steers the story in a different direction and gets you to look at a subject differently.

Well that happened to me during the Southeastern Medical Association Conference  held here in Atlanta recently.  One of the panelists was speaking during a session called successful pathways to medical device innovation, when all of a sudden he paused - and started talking about China and its potential impact on the med-tech landscape here in the U.S.

Instead of the same old song and dance of China becoming an emerging market and ripe opportunity for U.S. companies to take part in, the speaker made it sound like the nation was a competing market that was going to eventually take share away from U.S. device makers.

And these weren’t the musings of one lone med-device executive.

Recently I spoke with consulting firm Sagentia’s CEO Brent Hudson, who echoed similar statements – albeit nearly at the end of our conversation.

He noted that the Western med-tech firms are aware of China becoming a dominant player in the space and said that med-tech companies are trying various approaches to get a handle on the expansion into the Western market.

“I don’t speak to a single company that isn’t worried about it. Some are trying a partnership approach with say, Chinese device manufacturers,” Hudson told me.  He added that others were trying a more dominant approach.

 I think the take away from all this, is that the deeper story isn’t so much that these plush new emerging markets are waiting for U.S. markets to come to them.  I think the real key point is, these overseas ‘emerging markets’ are competitors and could have the potential to take away significant market share from U.S. firms.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Sept. 22, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for September 22, 2023.
  • Hands holding torn contract

    Quite a fix: Orthofix sacks three top execs

    BioWorld MedTech
    Orthofix Medical Inc. terminated its CEO, chief financial officer and chief legal officer in a move that plunged the stock from $18.63 at Monday’s close to $13.01...
  • New NLRP3 inflammasome inhibitors named in PTC Therapeutics patent

    BioWorld Science
    PTC Therapeutics Inc. has patented new NLRP3 inflammasome inhibitors reported to be useful...
  • Illustration of Alzheimer’s in the brain.

    Study identifies cause of death for Alzheimer’s neurons

    BioWorld
    By creating a new mouse model of Alzheimer’s disease that better recapitulated how the disease plays out in humans, investigators at KU Leuven have gained new...
BioFuture ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing